Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin

Phase 1

Withdrawn

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab
Drug: Pemetrexed
Drug: Carboplatin
Drug: ADI PEG20

First Posted Date: 2018-04-13

Last Posted Date: 2020-02-25

Lead Sponsor: Queen Mary University of London

Registration Number: NCT03498222

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Atezolizumab
Procedure: Stereotactic radiosurgery (SRS)

First Posted Date: 2018-03-29

Last Posted Date: 2024-08-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03483012

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Rogaratinib (BAY1163877)
Drug: Atezolizumab

First Posted Date: 2018-03-22

Last Posted Date: 2024-08-15

Lead Sponsor: Bayer

Target Recruit Count: 37

Registration Number: NCT03473756

Locations: 🇯🇵
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
🇦🇹
Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria
🇦🇹
Krankenhaus der Barmherzigen Brüder, Vienna, Wien, Austria

and more 27 locations

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: atezolizumab
Radiation: Low- Dose, Local Radiotherapy

First Posted Date: 2018-03-14

Last Posted Date: 2021-01-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT03465891

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Radiation: SABR
Drug: Atezolizumab

First Posted Date: 2018-03-14

Last Posted Date: 2023-07-19

Lead Sponsor: Peter MacCallum Cancer Centre, Australia

Target Recruit Count: 54

Registration Number: NCT03464942

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Phase 2

Active, not recruiting

Conditions: NHL
DLBCL

Interventions: Drug: Atezolizumab

First Posted Date: 2018-03-13

Last Posted Date: 2024-08-21

Lead Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland

Target Recruit Count: 109

Registration Number: NCT03463057

Locations: 🇧🇪
BE-Brugge-AZBRUGGE, Brugge, Belgium
🇳🇱
NL-Amersfoort-MEANDERMC, Amersfoort, Netherlands
🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands

and more 29 locations

A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 3

Terminated

Conditions: Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions: Drug: Atezolizumab
Drug: Placebo

First Posted Date: 2018-03-02

Last Posted Date: 2024-10-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 406

Registration Number: NCT03452137

Locations: 🇺🇸
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States
🇺🇸
Cleveland Clinic; Taussig Cancer Institute, Cleveland, Ohio, United States
🇧🇷
Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil

and more 132 locations

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Phase 2

Conditions: Stomach Cancer
Gastro Esophageal Junction Cancer

Interventions: Drug: Atezolizumab
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Docetaxel

First Posted Date: 2018-02-28

Last Posted Date: 2021-04-20

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03448835

Locations: 🇳🇱
Marieke van de Belt, Amsterdam, Netherlands
🇳🇱
Catharina ziekenhuis, Eindhoven, Netherlands

Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: CMP-001
Drug: Atezolizumab
Radiation: Radiation Therapy

First Posted Date: 2018-02-19

Last Posted Date: 2022-08-03

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT03438318

Locations: 🇺🇸
University of Colorado Aurora, Aurora, Colorado, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 2 locations

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Sorafenib
Drug: Bevacizumab

First Posted Date: 2018-02-15

Last Posted Date: 2023-10-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 558

Registration Number: NCT03434379

Locations: 🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇩🇪
Campus Virchow-Klinikum Charité Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie, Berlin, Germany
🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

and more 116 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy